GPP
Great Point Partners Portfolio holdings
AUM
$154M
This Quarter Return
+12.46%
1 Year Return
-2.36%
3 Year Return
+169.3%
5 Year Return
+292.82%
10 Year Return
+3,519.88%
AUM
$447M
AUM Growth
+$447M
(+5.8%)
Cap. Flow
+$20M
Cap. Flow
% of AUM
4.46%
Top 10 Holdings %
Top 10 Hldgs %
53.82%
Holding
50
New
14
Increased
13
Reduced
3
Closed
14
Top Buys
| 1 |
Galapagos
GLPG
|
$16.5M |
| 2 |
Relmada Therapeutics
RLMD
|
$16.2M |
| 3 |
Sarepta Therapeutics
SRPT
|
$13.1M |
| 4 |
BCYC
Bicycle Therapeutics
BCYC
|
$12.2M |
| 5 |
Avidity Biosciences
RNA
|
$11.9M |
Top Sells
| 1 |
KDMN
Kadmon Holdings, Inc.
KDMN
|
$29.4M |
| 2 |
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
|
$16.1M |
| 3 |
United Therapeutics
UTHR
|
$16M |
| 4 |
Biogen
BIIB
|
$13.4M |
| 5 |
SAGE
Sage Therapeutics
SAGE
|
$11.9M |
Sector Composition
| 1 | Healthcare | 99.67% |
| 2 | Real Estate | 0.33% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ARNA
1
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $49.3M | 10.96% | 530,670 | – | – |
|
2
Exelixis
EXEL
$10.1B
| $32M | 7.11% | 1,750,000 +225,000 | +15% | +$4.11M |
|
3
Xenon Pharmaceuticals
XENE
$2.98B
| $29.7M | 6.59% | 950,000 +250,000 | +36% | +$7.81M |
|
4
Travere Therapeutics
TVTX
$1.56B
| $24.8M | 5.52% | 800,000 +175,000 | +28% | +$5.43M |
|
5
AnaptysBio
ANAB
$569M
| $20.6M | 4.57% | 592,250 +42,705 | +8% | +$1.48M |
|
6
Vertex Pharmaceuticals
VRTX
$100B
| $18.7M | 4.15% | 85,000 | – | – |
|
7
BioAtla
BCAB
$26.7M
| $17M | 3.77% | 864,300 +20,298 | +2% | +$398K |
|
|
8
Galapagos
GLPG
$2.07B
| $16.5M | 3.67% | +300,000 | New | +$16.5M |
|
|
9
Relmada Therapeutics
RLMD
$37.2M
| $16.2M | 3.59% | +717,320 | New | +$16.2M |
|
10
MacroGenics
MGNX
$112M
| $16.1M | 3.57% | 1,000,000 | – | – |
|
11
Cytokinetics
CYTK
$4.23B
| $16M | 3.54% | 350,000 -41,429 | -11% | -$1.89M |
|
|
TCDA
12
DELISTED
Tricida, Inc. Common Stock
TCDA
| $13.4M | 2.97% | 1,400,000 -574,000 | -29% | -$5.49M |
|
13
Rigel Pharmaceuticals
RIGL
$697M
| $13.3M | 2.94% | 5,000,000 +3,020,000 | +153% | +$8M |
|
|
14
Sarepta Therapeutics
SRPT
$1.78B
| $13.1M | 2.91% | +145,405 | New | +$13.1M |
|
|
BCYC
15
Bicycle Therapeutics
BCYC
$511M
| $12.2M | 2.7% | +200,000 | New | +$12.2M |
|
16
Vaxcyte
PCVX
$4B
| $11.9M | 2.64% | 500,000 +401,939 | +410% | +$9.56M |
|
|
17
Avidity Biosciences
RNA
$5.99B
| $11.9M | 2.64% | +500,000 | New | +$11.9M |
|
18
Aclaris Therapeutics
ACRS
$209M
| $11.6M | 2.58% | 800,000 +300,000 | +60% | +$4.36M |
|
19
Rocket Pharmaceuticals
RCKT
$354M
| $10.9M | 2.43% | 500,526 -264,474 | -35% | -$5.77M |
|
|
SLN
20
Silence Therapeutics
SLN
$227M
| $10.6M | 2.36% | +444,443 | New | +$10.6M |
|
21
Dyne Therapeutics
DYN
$1.92B
| $10M | 2.23% | 845,000 +100,000 | +13% | +$1.19M |
|
22
Passage Bio
PASG
$22.7M
| $9.64M | 2.14% | +1,518,095 | New | +$9.64M |
|
23
ProQR Therapeutics
PRQR
$237M
| $8.98M | 2% | 1,121,122 +1,090,786 | +3,596% | +$8.74M |
|
24
UroGen Pharma
URGN
$900M
| $8.31M | 1.85% | 873,424 +123,424 | +16% | +$1.17M |
|
|
KDNY
25
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $6.36M | 1.41% | +390,041 | New | +$6.36M |
|